Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Anthony Letai
Dana Farber Cancer Inst, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Vivid Biosciences
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
NA
Comprehensive dissection of the CLL genome and phenome to improve patient outcomes
Project Narrative The goals of precision medicine have been articulated as delivering the right drug, for the right patient, at the right time. In CLL, we have an opportunity to actualize this vision, and this Program has been specifically constructed to integrate the needed facets and hence to constructively advance this vision. Recent advances on both the therapeutic side (with the new availability of a host of new clinically active agents), and on the scientific side (with the development of novel sequencing tools and high throughput approaches for functional inquiry) have arrived at a critical stage such that it is possible to now bring all these data layers together, as we propose in this application, such that individual patients can be matched with specific tailored therapies.
Filed on June 19, 2018.
Tell us what you know about Anthony Letai's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Anthony Letai”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Anthony Letai | Brigham and Women's Hospital | Conflict of Interest | Vivid | $20,000 - $39,999 |
| Anthony Letai | Brigham and Women's Hospital | Conflict of Interest | Vivid | Value cannot be readily determined |
| Anthony Letai | Dana Farber Cancer Inst | Conflict of Interest | Vivid Biosciences | Value cannot be readily determined |
| Anthony Letai | Dana Farber Cancer Inst | Conflict of Interest | Vivid Biosciences | $20,000 - $39,999 |
| Anthony Letai | Dana Farber Cancer Inst | Conflict of Interest | Vivid Biosciences | $20,000 - $39,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.